Invention Grant
US09540351B2 Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
有权
3,5-二氨基吡唑激酶抑制剂的药学上可接受的盐
- Patent Title: Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
- Patent Title (中): 3,5-二氨基吡唑激酶抑制剂的药学上可接受的盐
-
Application No.: US14489231Application Date: 2014-09-17
-
Publication No.: US09540351B2Publication Date: 2017-01-10
- Inventor: Tai Wei Ly , Erik Dean Raaum
- Applicant: AXIKIN PHARMACEUTICALS, INC.
- Applicant Address: US CA San Diego
- Assignee: Axikin Pharmaceuticals, Inc.
- Current Assignee: Axikin Pharmaceuticals, Inc.
- Current Assignee Address: US CA San Diego
- Agency: Jones Day
- Main IPC: C07D403/12
- IPC: C07D403/12 ; C07D231/38 ; A61K31/415 ; A61K31/496 ; A61K31/5377 ; C07D401/12 ; A61K31/4439 ; A61K31/4178 ; A61K31/4184 ; C07C53/08 ; C07C53/02 ; C07C309/44 ; C07C309/04 ; C07C59/255 ; C07C309/30 ; C07C53/18
Abstract:
Provided herein are pharmaceutically acceptable salts of 3,5-diaminopyrazoles, for example, pharmaceutically acceptable salts of compounds of Formula IA, that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition.
Public/Granted literature
- US20150080397A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS Public/Granted day:2015-03-19
Information query
